MoonLake Q3 2025: $380.5M cash, positive Phase 2 PPP data for Sonelokimab

MoonLake Immunotherapeutics

2025-Q3 EPS reported -$2.61

Cash and equivalents $380.5M as of Sept 30, 2025; runway into H2 2027.
R&D expenses $60.6M (up from $49.8M) driven by trial ramp-up and BLA prep.
Phase 2 LEDA PPP: 64% mean PPPASI reduction, 39% PPPASI75 at week 16; no approved therapies.
VELA-TEEN interim: 46% HiSCR75 in adolescent HS at week 16 (n=11); BLA submission Q3/Q4 2026.
FDA Type B meeting Dec 15, 2025 to discuss SLK in HS evidence for BLA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.